A comparison between GnRH agonist and antagonist analogs for controlled ovarian stimulation in overweight/obese women with PCOS after ICSI
Keywords:
GnRH analogues, ovarian stimulation, overweight/obese, PCOS, ICSIAbstract
Background: polycystic ovary syndrome (PCOS) is the most common endocrine disorder of reproductive age females with a prevalence of 10%. Obesity is one of its characteristic association with a prevalence of 40-60%, usually leads to reduce fertility, lower pregnancy potential and increase pregnancy loss. Aim of the study: to decide the better gonadotropin releasing hormone (GnRH) analogues down regulation protocol for overweight/obese PCOS women by studying ICSI outcome in form of ovarian response, embryos’ quality, pregnancy rate and OHSS development. Material & methods: Forty sub-fertile women with PCOS whom their body mass index (BMI) ≥ 26 were included in the study. Their male partners had mild to moderate impairment in semen quality. All are subjected to COS by GnRH analogues and separated into 2 groups; group 1: down regulated by GnRH antagonist (n=14) and group 2: down regulated by GnRH agonist (n=26). Results: not significant difference between both groups concerning ovarian response. Pregnancy rate was greater and the rate of developing OHSS was lower in GnRH antagonist group with non-significant statistical difference 57.1% vs 38.5% and 0% vs 7.7% respectively. Conclusions: both GnRH antagonist and agonist had the same efficacy when used during COS/ICSI for overweight/obese PCOS, but had lower safety in favor of GnRH antagonist protocol.
Downloads
References
Chen R, Chen S, Liu M, He H, Xu H, Liu H, Du H, Wang W, Xia X, Liu J. Pregnancy outcomes of PCOS overweight/obese patients after controlled ovarian stimulation with the GnRH antagonist protocol and frozen embryo transfer. Reproductive Biology and Endocrinology. 2018 Dec;16(1):1-6.
Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. American journal of obstetrics and gynecology. 2011 Jun 1;204(6):558-e1.
Chemerinski A, Cooney L, Shah D, Butts S, Gibson-Helm M, Dokras A. Knowledge of PCOS in physicians-in-training: identifying gaps and educational opportunities. Gynecological Endocrinology. 2020 Oct 2;36(10):854-9.
Sam S. Obesity and polycystic ovary syndrome. Obesity management. 2007 Apr 1;3(2):69-73.
Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. International journal of obesity. 2002 Jul;26(7):883-96.
Homburg R, Berkowitz D, Levy T, Feldberg D, Ashkenazi J, Ben-Rafael Z. In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome. Fertility and Sterility. 1993 Nov 1;60(5):858-63.
Kim CH, Moon JW, Kang HJ, Ahn JW, Kim SH, Chae HD, Kang BM. Effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase compared with GnRH agonist long protocol in non-obese and obese patients with polycystic ovary syndrome undergoing IVF/ICSI. Clinical and experimental reproductive medicine. 2012 Mar;39(1):22.
Al‐Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews. 2016(4).
Behery MA, Hasan EA, Ali EA, Eltabakh AA. Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study. Middle East Fertility Society Journal. 2020 Jan;24(1):1-7.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. The Journal of Clinical Endocrinology & Metabolism. 2006 Nov 1;91(11):4237-45.
Ye H, Huang GN, Pei L. A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization. Zhonghua fu Chan ke za zhi. 2001 Apr 1;36(4):222-5.
Behery MA, Hasan EA, Ali EA, Eltabakh AA. Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study. Middle East Fertility Society Journal. 2020 Jan;24(1):1-7.
Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P, Frydman R. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertility and sterility. 2000 Feb 1;73(2):314-20.
Lin H, Li Y, Li L, Wang W, Yang D, Zhang Q. Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs. PloS one. 2014 Mar 18;9(3):e91796.
Bahçeci M, Ulug U, Ben-Shlomo I, Erden HF, Akman MA. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. The Journal of reproductive medicine. 2005 Feb 1;50(2):84-90.
Kim CH, Moon JW, Kang HJ, Ahn JW, Kim SH, Chae HD, Kang BM. Effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase compared with GnRH agonist long protocol in non-obese and obese patients with polycystic ovary syndrome undergoing IVF/ICSI. Clinical and experimental reproductive medicine. 2012 Mar;39(1):22.
Kadoura S, Alhalabi M, Nattouf AH. Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis. Scientific reports. 2022 Mar 15;12(1):1-22.
Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS?. Reproductive biomedicine online. 2012 Jan 1;24(1):6-22.
Fauser BC. Publication of the results in all Dutch centers for in vitro fertilization: an important step towards an improvement in the effectiveness of the treatment. Nederlands tijdschrift voor geneeskunde. 2002 Dec 1;146(49):2335-8.
Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. The Journal of Clinical Endocrinology & Metabolism. 2003 Jan 1;88(1):166-73.
Johnston-MacAnanny EB, DiLuigi AJ, Engmann LL, Maier DB, Benadiva CA, Nulsen JC. Selection of first in vitro fertilization cycle stimulation protocol for good prognosis patients: gonadotropin releasing hormone antagonist versus agonist protocols. The Journal of reproductive medicine. 2011 Jan 1;56(1-2):12-6.
Depalo R, Jayakrishan K, Garruti G, Totaro I, Panzarino M, Giorgino F, Selvaggi LE. GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). Reproductive biology and endocrinology. 2012 Dec;10(1):1-8.
Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Aboulfoutoh I, van Wely M. The updated Cochrane review 2014 on GnRH agonist trigger: an indispensable piece of information for the clinician. Reproductive biomedicine online. 2016 Feb 1;32(2):259-60.
Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertility and sterility. 2008 Jan 1;89(1):84-91.
Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Human Reproduction. 2002 Apr 1;17(4):874-85
Hernández PA, Ramírez EG, Soto AP, Alzate CA, Pereira ML, Jimenez CF, Gonzalez DY. Fisioterapia y rehabilitación integral de personas con discapacidad: revisión narrativa. Archivos Venezolanos de Farmacología y Terapéutica. 2021;40(6):648-55.
Sierra CS, Hernández YG, Rojas DM, Gómez RM, Tovar CV. Condiciones inseguras de las políticas públicas ambientales en cooperativas de recicladores de residuos sólidos urbanos. Archivos Venezolanos de Farmacología y Terapéutica. 2021;40(8):818-23.
Diaz CI, Zambrano AD, Naranjo AL, Shiguango NN, Carrasco AP, Córdova HS, Proaño CA, Diaz LC. Diabetes mellitus tipo 2 y su asociación con factores de riesgo cardiovascular en pacientes hipertensos. Diabetes Internacional. 2018;10(1):8-13.
Zhu J, Zhang J, Yang J, Li D, Wang C, Elizur SE, Zhao K, Kuang Y, Wang Y. A comprehensive evaluation of progestin-primed ovarian stimulation protocol in patients with or without PCOS undergoing in vitro fertilization. Reproductive Biology. 2021 Dec 1;21(4):100540.
Elabd MM, Orief YI, Gwely GM. Role of follicular fluid leptin hormone in women with polycystic ovarian syndrome in assisted reproductive technology. Journal of The Arab Society for Medical Research. 2021 Jan 1;16(1):75.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 AVFT – Archivos Venezolanos de Farmacología y Terapéutica
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
